NVCR
NVCR clinical trials: NovoCure Ltd
Every trial on ClinicalTrials.gov where NovoCure Ltd is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 76
- Trials linked
- 28
- As lead sponsor
- 48
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
NVCR on the catalyst calendar · NVCR registry changes
- Primary completion Oct 2028Sponsor estimatePhase 3NCT06216301LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNovoCure GmbH · Metastatic Non-small Cell Lung CancerRecruitingNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2029Sponsor estimatePhase 3NCT06556563EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaNovoCure GmbH · GlioblastomaActive, not recruitingNVCRLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 19, 2026ActualNo phase registeredNCT04471844Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBMNovoCure Ltd. · Glioblastoma MultiformeCompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 18, 2025ActualPhase 2NCT06390059EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for...NovoCure Ltd. · Metastatic Pancreatic Ductal AdenocarcinomaCompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 23, 2026ActualPhase 2NCT06558799LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell...NovoCure GmbH · Non-Small Cell Lung Cancer (NSCLC)TerminatedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 24, 2024ActualPhase 3NCT02973789Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell...NovoCure GmbH · Nonsmall Cell Lung CancerCompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 16, 2024ActualPhase 3NCT03377491Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant...NovoCure Ltd. · Pancreas AdenocarcinomaCompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT07319910Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With...NovoCure GmbH · Locally Advanced Pancreatic AdenocarcinomaTemporarily not availableNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 29, 2024ActualPhase 3NCT02831959Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From...NovoCure GmbH · Brain Metastases From Non-small Cell Lung Cancer (NSCLC)CompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimateNo phase registeredNCT05538806TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma StudyNovoCure Ltd. · Pleural MesotheliomaRecruitingNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 10, 2025ActualPhase 2NCT04892472EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for...NovoCure GmbH · Non-small Cell Lung CancerTerminatedNVCRLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2029Sponsor estimateNo phase registeredNCT06924099TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)NovoCure Ltd. · GlioblastomaRecruitingNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 7, 2024ActualNo phase registeredNCT04281576Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable...NovoCure Ltd. · Gastric CancerCompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 14, 2021ActualPhase 2NCT03606590Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)NovoCure Ltd. · Hepatocellular CarcinomaCompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 20, 2023ActualPhase 2NCT04492163Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBMNovoCure GmbH · Glioblastoma MultiformeCompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 18, 2023ActualPhase 3NCT03940196Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer...NovoCure Ltd. · Ovarian CancerCompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2024Sponsor estimateNo phase registeredNCT04717739TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning StudyNovoCure Ltd. · GlioblastomaUnknown statusNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 26, 2021ActualNo phase registeredNCT04953234Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19...NovoCure GmbH · COVID-19CompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2021Sponsor estimateNo phase registeredNCT03258021TTFields In GErmany in Routine Clinical CareNovoCure Ltd. · GlioblastomaUnknown statusNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2019Sponsor estimateNo phase registeredNCT03780569TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBMNovoCure Ltd. · Glioblastoma MultiformeUnknown statusNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2018ActualPhase 2NCT02397928Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma...NovoCure Ltd. · Malignant Pleural MesotheliomaCompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2017Sponsor estimatePhase 1/Phase 2NCT01971281Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for...NovoCure Ltd. · Pancreatic AdenocarcinomaUnknown statusNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 3NCT00916409Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)NovoCure Ltd. · Glioblastoma MultiformeCompletedNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016Sponsor estimatePhase 1/Phase 2NCT02244502Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)NovoCure Ltd. · Ovarian CarcinomaUnknown statusNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2017Sponsor estimatePhase 2NCT01755624Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local...NovoCure Ltd. · 1-5 Brain Metastases From Non-Small Cell Lung CancerUnknown statusNVCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 51 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner